Jonathan Knowles is an associate in the Intellectual Property group in Axinn’s New York office. His practice focuses primarily on intellectual property litigation. Jonathan is particularly experienced in pharmaceutical and biochemical patent litigation. He counsels clients about IP and regulatory issues and maintains an active pro bono caseload.
Jonathan received his law degree from Columbia Law School, where he was a James Kent Scholar. During his time at Columbia, Jonathan worked for the school’s environmental law clinic and interned at the New York City Law Department. Jonathan received his BA cum laude from Carleton College, with a major in biology and a concentration in biochemistry. Jonathan was a Summer Associate with Axinn in 2017.
- New York Intellectual Property Law Association
- American Bar Association
- Volunteer Lawyers for the Arts
- Axinn IP Update: SCOTUS Passes on Refining Subject Matter Eligibility Doctrine, Axinn Update, January 13, 2020
- U.S. Government Patent Enforcement: A Ripple or a Coming Tempest?, IPWatchdog, November 25, 2019
- FDA's Aggressive Enforcement Against Stem Cell Companies Starting to Ripen, Bloomberg BNA Insights, June 27, 2019
- Biologic Labels and Induced Patent Infringement: A Perspective on Evolving U.S. Law, BioProcess International, May 17, 2019
- Axinn IP Update: FDA Issues Final Guidance on Interchangeability of Biologics, Axinn Update, May 14, 2019
- FDA Doubles Down in Its Updated Biologics Naming Guidance, The Center for Biosimilars, March 19, 2019
- Axinn IP Update: Hikma Pharmaceuticals USA, Inc. v. Vanda Pharmaceuticals, Inc., Axinn Update, March 18, 2019
- Stem Cell Companies Beware: FDA May Come Knocking, Bloomberg BNA Insights, January 28, 2019
- JD, James Kent Scholar – Columbia Law School (2018)
- BA, cum laude – Carleton College (2014)
- New York